Cisplatin reduces endothelial cell migration via regulation of type 2-matrix metalloproteinase activity

Cellular Physiology and Biochemistry

Volumn 23, Issue 4-6, 2009, Pages 441-448

  Montiel, Mercedes ^a   Urso, Loredana ^b   De La Blanca, Enrique Pérez ^a   Marsigliante, Santo ^b   Jiménez, Eugenio ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b UNIVERSITY OF SALENTO   (Italy)

Author keywords

Cell migration; Cell viability; Cisplatin; Endothelial cells; Matrix metalloproteinases; Mitogen activated protein kinases

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CISPLATIN; GELATINASE A; GELATINASE B; ILOMASTAT; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CELL LYSATE; CELL MIGRATION; CYTOTOXICITY; DRUG ACTIVITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 66749118317     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218191     Document Type: Article

References (35)

1. Bland ML, Desclozeaux M, Ingraham HA: Tissue growth and remodeling of the embryonic and adult adrenal gland. Ann N Y Acad Sci 2003;995:59-72.
2. Li S, Huang NF, Hsu S: Mechanotransduction in endothelial cell migration. J Cell Biochem 2005;96:1110-1126.
3. Yamaguchi H, Wyckoff J, Condeelis J: Cell migration in tumors. Curr Opin Cell Biol 2005;17:559-564.
4. Lamalice L, Le Boeuf F, Huot J: Endothelial cell migration during angiogenesis. Circ Res 2007;100:782-794.
5. Huang C, Jacobson K, Schaller MD: MAP kinases and cell migration. J Cell Sci 2004;117:4619-4628.
6. Xia Y, Karin M: The control of cell motility and epithelial morphogenesis by Jun kinases. Trend Cell Biol 2004;14:94-101.
7. Mehta PK, Griendling KK: Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007;292:C82-97.
8. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T: Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003;253:269-85.
9. Yan C, Boyd DD: Regulation of matrix metalloproteinase gene expression. J Cell Physiol 2007;211:19-26.
10. Nagase H, Visse R, Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-573.
11. Page-McCaw A, Ewald AJ, Werb Z: Matrix metalloproteinases and the regulation of tissue remodeling. Nat Rev Mol Cell Biol 2007;8:221-233.
12. Haas TA. Endothelial cell regulation of matrix metalloproteinases: Can J Physiol Pharmacol 2005;83:1-7.
13. Sluijter JP, de Kleijn DP, Pasterkamp G: Vascular remodeling and protease inhibition-bench to bedside. Cardiovasc Res 2006;69:595-603.
14. Deryugina EI, Quigley JP: Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006;25:9-34.
15. Fuertes MA, Castilla J, Alonso C, Pérez JM: Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 2003;10:257-266.
16. Wang G, Reed E, Li QQ: Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer. Oncol Rep 2004;12:955-965.
17. Havelka AM, Berndtsson M, Olofsson MH, Shoshan MC, Linder S: Mechanisms of action of DNA-damaging anticancer drugs in treatment of carcinomas: is acute apoptosis an "off-target" effect? Mini Rev Med Chem 2007;7:1035-1039.
18. Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973;52:2745-2756.
19. Montiel M, Pérez de la Blanca E, Jiménez E: Angiotensin II induces focal adhesion kinase/paxillin phosphorylation and cell migration in human umbilical vein endothelial cells. Biochem Biophys Res Commun 2005;327:971-978.
20. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
21. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM: Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007;7:3-18.
22. Price PM, Yu F, Kaldis P, Aleem E, Nowak G, Safirstein RL, Megyesi J: Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2. J Am Soc Nephrol 2006;17:2434-2442.
23. Yu M, Han J, Cui P, Dai M, Li H, Zhang J, Xiu R: Cisplatin up-regulates ICAM-1 expression in endothelial cell via a NF-?κB dependent pathway. Cancer Sci 2008;99:391-397.
24. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
25. Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY: Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol. 2005;7:909-915.
26. Morikawa T, Shibuya M, Sakai S, Kudo S: Effect of anticancer drugs on invasive capacity of human small-cell lung cancer cells in vitro. Nippon Ika Daigaku Zasshi 1995;62:320-328.
27. Ramer R, Eichele K, Hinz B: Upregulation of tissue inhibitor of matrix metalloproteinases-1 confers the antiinvasive action of cisplatin on human cancer cells. Oncogene 2007;26:5822-5827.
28. Sasanelli R, Boccarelli A, Giordano D, Laforgia M, Arnesano F, Natile G, Cardellicchio C, Capozzi MA, Coluccia M: Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl) methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12. J Med Chem 2007;50:3434-3441.
29. Xue M, March L, Sambrook PN, Jackson CJ: Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: relevance to inflammation in rheumatoid arthritis. Arthritis Rheum 2007;56:2864-2874.
30. Brozovic A, Osmak M: Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007;251:1-16.
31. Losa JH, Parada Cobo C, Viniegra JG, Sanchez-Arevalo Lobo VJ, Ramón y Cajal S, Sanchez-Prieto R: Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 2003;22:3998-4006.
32. Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M, Kaina B: Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 2004;112:974-985.
33. Liang KC, Lee CW, Lin WN, Lin CC, Wu CB, Luo SF, Yang CM: Interleukin-1β induces MMP-9 expression via p42/ p44 MAPK, p38 MAPK, JNK, and nuclear factor-κB signaling pathways in human tracheal smooth muscle cells. J Cell Physiol 2007;211:759-770.
34. Ispanovic E, Haas TL: JNK and PI3K differentially regulate MMP-2 and MT1-MMP mRNA and protein in response to actin cytoskeleton reorganization in endothelial cells. Am J Physiol Cell Physiol 2006;291:C579-588.
35. Yu J, Bian D, Mahanivong C, Cheng RK, Zhou W, Huang S: p38 Mitogen-activated protein kinase regulation of endothelial cell migration depends on urokinase plasminogen activator expression. J Biol Chem 2004;279:50446-50454.